THE RIGHT THERAPY MATTERS
HAE ATTACKS MAY IMPACT YOUR PATIENTS MORE THAN YOU THINK
86% of patients said that 3 in 4 untreated or inadequately controlled attacks were severe enough to negatively impact quality of life.1
97% of patients agree nothing could be more convenient than a medication that allows them to live attack free.2
* These findings are the result of an online survey conducted by The Harris Poll, sponsored by CSL Behring LLC, involving 100 US adults aged 18+ who have been diagnosed by a healthcare professional with hereditary angioedema (HAE) ("people living with HAE") and 150 licensed allergists/immunologists in the US who have treated/managed at least 2 HAE patients in the past 12 months ("physicians").
BUILD AND MAINTAIN STEADY‑STATE C1‑INH FUNCTIONAL LEVELS
HAEGARDA replaces missing or dysfunctional C1‑INH with functional C1‑INH, which regulates the normal production of bradykinin
- The root cause of HAE is deficient or dysfunctional C1-INH
- Functional C1-INH levels ≥40% of normal are proposed to reduce the risk of HAE attacks3
- Steady-state C1-INH functional activity is expected within 3 to 4 doses4
What made me try HAEGARDA? It’s the same protein my body is lacking.
-Zahra, HAEGARDA Advocate
C1-INH=C1 inhibitor.
HAE=hereditary angioedema.
The 2021 World Allergy Organization Guidelines recommend use of C1 esterase inhibitors for first-line, long-term prophylaxis.6
The right therapy matters to get to steady state quickly
- Quick acting: steady-state C1‑INH functional levels achieved in approximately the first 2 weeks†
- Subcutaneous C1-INH builds and maintains steady-state C1‑INH functional activity3-5‡
Administered subcutaneously, HAEGARDA 60 IU/kg maintained steady-state C1‑INH functional levels above 40%3-5
† Steady state is expected within 3 to 4 doses.
‡ The plasma levels of C1-INH functional activity were evaluated in patients with type 1 or type 2 HAE in a Phase 3, placebo-controlled, crossover study. Patients received twice-weekly subcutaneous injections of HAEGARDA 40 IU/kg or 60 IU/kg for 16 weeks. The model-derived outcome is the steady-state C1-INH functional activity vs time.4
What makes HAEGARDA different?
HAEGARDA is the HAE product that reduced HAE attacks by 95%.‡
‡ Median reduction in the number of attacks with HAEGARDA 60 IU/kg vs placebo.